A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Children's Oncology Group
Astellas Pharma Inc
Delta-Fly Pharma, Inc.
Astellas Pharma Inc
National Cancer Institute (NCI)
Children's Oncology Group
Technische Universität Dresden
Cornerstone Pharmaceuticals
Children's Oncology Group
University of Birmingham
University of Ulm
Polish Adult Leukemia Group
Children's Oncology Group
Pfizer
Ludwig-Maximilians - University of Munich
University of Ulm
German CLL Study Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
St. Jude Children's Research Hospital
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Acute Leukemia French Association